Correlates of Dolutegravir Resistance in Low- and Middle-Income Countries: A Combined Analysis of Drug Resistance Surveys in 4 Countries

Résumé fourni par la source

BACKGROUND: Dolutegravir (DTG)-based regimens (DBR) account for >97% of antiretroviral drugs dispensed through President's Emergency Plan for AIDS Relief. Understanding factors associated with DTG drug resistance (DR) is critical to safeguarding its long-term efficacy. METHODS: We included adults on DBR from cohorts in Malawi, Mozambique, Uganda and Ukraine (2020-2022) with successful genotypes. DTG DR was defined as Stanford HIV Drug Resistance Database genotypic susceptibility score >15. Logistic regression assessed associations between DTG DR and clinical/sociodemographic factors, reporting odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Median age was 36.2 years; 59% were female; 89% transitioned to DTG from a prior regimen. In a multivariable analyses including findings from genotype test, male sex (OR 2.02, 95% CI 1.10-3.73), any NRTI resistance (OR 31.17, 95% CI 12.93-75.14), and any NNRTI resistance (OR 2.56, 95% CI 1.12-5.88) were associated with DTG DR. After excluding genotype-derived variables, male sex remained associated with DTG DR (OR 2.13, 95% CI 1.28-3.54), while participants receiving zidovudine-containing backbones had higher odds of DTG DR compared with those receiving tenofovir-containing backbones (OR 5.87, 95% CI 2.45-14.07). Among individuals with DTG DR, G118R was the most frequent major mutation. M184V demonstrated high sensitivity (83%) and specificity (91%) for detecting DTG resistance. CONCLUSIONS: These findings identify key clinical correlates of DTG resistance, including concurrent NRTI/NNRTI resistance and zidovudine-containing regimens, which may serve as proxies for prior viral non-suppression and help inform more targeted drug resistance testing and regimen optimization in settings where genotypic testing is not readily available.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.